<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals Limited has submitted its annual disclosure to BSE and NSE confirming it does not qualify as a Large Corporate under SEBI's framework as of 31st March 2025. The filing was made per SEBI Circular dated October 19, 2023, and covers the FY 2025-2026 block period. Outstanding borrowings and credit rating fields are marked as 'Not applicable' since the company falls outside the Large Corporate criteria. The disclosure was signed by the Company Secretary and CFO on May 9, 2025.
This is a routine regulatory compliance filing with no material impact on shareholders or stock price. It simply confirms the company does not meet the SEBI-defined Large Corporate threshold and is not obligated to mandatorily raise funds from the debt market.